Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine

Anti-Cancer Drugs

Volumn 17, Issue 2, 2006, Pages 181-187

  Bressin, Céline ^a   Bourgarel Rey, Véronique ^a   Carré, Manon ^a   Pourroy, Bertrand ^a   Arango, Diego ^b   Braguer, Diane ^a   Barra, Yves ^a  

^a CNRS   (France)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antisense; Apoptosis; C myc; Sensitivity; Vinblastine

Indexed keywords

CYTOCHROME C; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN P53; TRANSCRIPTION FACTOR; VINBLASTINE; VINCA ALKALOID;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; DRUG SENSITIVITY; GENE ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; ONCOGENE C MYC; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; WILD TYPE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; COLONIC NEOPLASMS; CYTOCHROMES C; DNA, ANTISENSE; DOWN-REGULATION; DRUG TOLERANCE; G1 PHASE; HUMANS; MEMBRANE POTENTIALS; MITOCHONDRIA; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VINBLASTINE;

EID: 33646236796     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200602000-00009     Document Type: Article

References (39)

1. Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci 1998; 3:d250-d268.
2. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003; 22:9007-9021.
3. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene 1999; 18:2967-2987.
4. Biroccio A, Benassi B, Filomeni G, Amodei S, Marchini S, Chiorino G, et al. Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells. J Biol Chem 2002; 277:43763-43770.
5. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18:3004-3016.
6. Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 2004; 6:195-206.
7. Nesbit CE, Fan S, Zhang H, Prochownik EV. Distinct apoptotic responses imparted by c-myc and max. Blood 1998; 92:1003-1010.
8. Arango D, Mariadason JM, Wilson AJ, Yang W, Corner GA, Nicholas C, et al. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 2003; 89:1757-1765.
9. Kinashi Y, Akaboshi M, Masunaga S, Ono K, Watanabe M. Resistance to 195mPt-radiolabeled cis-diaminedichloroplatinum (II) of SHOK cells transfected with various oncogenes. Radiat Med 1998; 16:233-237.
10. Bottone MG, Soldani C, Tognon G, Gorrini C, Lazze MC, Brison O, et al.. Multiple effects of paclitaxel are modulated by a high c-myc amplification level. Exp Cell Res 2003; 290:49-59.
11. Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anticancer Drugs 2003; 14:39-47.
12. 1 arrest and a mitochondrial pathway. Mol Pharmacol 2004; 66:580-591.
13. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002; 2:1-17.
14. Goncalves A, Braguer D, Carles G, Andre N, Prevot C, Briand C. Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). Biochem Pharmacol 2000; 60:1579-2584.
15. Carre M, Andre N, Carles G, Borghi H, Brichese L, Briand C, et al. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem 2002; 277:33664-33669.
16. Andre N, Braguer D, Brasseur G, Goncalves A, Lemesle-Meunier D, Guise S, et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 2000; 60:5349-5353.
17. Andre N, Carre M, Brasseur G, Pourroy B, Kovacic H, Briand C, et al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett 2002; 532:256-260.
18. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003; 39:615-647.
19. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 2003; 3:291-306.
20. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999; 44:355-361.
21. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003; 116:4077-4085.
22. Roy B, Beamon J, Balint E, Reisman D. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 1994; 14:7805-7815.
23. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3:193-203.
24. Bourgarel-Rey V, El Khyari S, Rimet O, Bordas B, Guigal N, Braguer D, et al. Opposite effects of antimicrotubule agents on c-myc oncogene expression depending on the cell lines used. Eur J Cancer 2000; 36:1043-1049.
25. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001; 61:4910-4915.
26. Carles G, Braguer D, Sabeur G, Briand C. The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cells. Anticancer Drugs 1998; 9:209-221.
27. Garcia P, Braguer D, Carles G, Briand C. Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Anticancer Drugs 1995; 6:533-544.
28. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995; 377:446-448.
29. Scarlett JL, Sheard PW, Hughes G, Ledgerwood EC, Ku HH, Murphy MP. Changes in mitochondrial membrane potential during staurosporine-induced apoptosis in Jurkat cells. FEBS Lett 2000; 475:267-272.
30. Bourgarel-Rey V, Vallee S, Rimet O, Champion S, Braguer D, Desobry A, et al. Involvement of nuclear factor kappaB in c-Myc induction by tubulin polymerization inhibitors. Mol Pharmacol 2001; 59:1165-1170.
31. Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, et al. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998; 58:283-289.
32. Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, Mottolese M, et al. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 1999; 5:2588-2595.
33. Alexandrova N, Niklinski J, Bliskovsky V, Otterson GA, Blake M, Kaye FJ, et al. The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro. Mol Cell Biol 1995; 15:5188-5195.
34. El Khyari S, Bourgarel V, Barra Y, Braguer D, Briand C. Pretreatment by tubulin agents decreases C-MYC induction in human colon carcinoma cell line HT29-D4. Biochem Biophys Res Commun 1997; 231:751-754.
35. Niklinski J, Claassen G, Meyers C, Gregory MA, Allegra CJ, Kaye FJ, et al. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma. Mol Cell Biol. 2000; 20:5276-5284.
36. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54:3131-3135.
37. Reisman D, Elkind NB, Roy B, Beamon J, Rotter V. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 1993; 4:57-65.
38. Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP, et al. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 2001; 20:6983-6993.
39. Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, et al. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 1997; 15:2767-2772.